Searchable abstracts of presentations at key conferences in endocrinology

ea0086p7 | Adrenal and Cardiovascular | SFEBES2022

Adrenalectomy for unilateral primary aldosteronism improves quality of life: prospective analyses in the MATCH trial

Blackstone Brittany , Goodchild Emily , Tooze Oliver , Salsbury Jackie , Wu Xilin , Ronaldson Amy , Senanayake Russell , Bashari Waiel , Argentesi Giulia , O'Toole Samuel M. , Parvanta Laila , Sahdev Anju , Laycock Kate , Cruickshank Kennedy , Gurnell Mark , M. Drake William , Brown Morris J.

Background: After adrenalectomy (ADX) for primary aldosteronism (PA), approximately 30% of patients achieve clinical success (normalisation of home BP); many additional patients report feeling subjectively better. We used the non-randomised MATCH study1 to further assess quality of life (QoL) changes in participants.Objective: Assess QoL using the 36-item Short Form Health Survey (SF-36) after surgical treatment of unilateral PA and medical treatment of ...

ea0086p153 | Adrenal and Cardiovascular | SFEBES2022

Preliminary data from FABULAS: a Feasibility study of RadioFrequency endoscopic ABlation, with ULtrasound guidance, as a non-surgical, Adrenal Sparing treatment for aldosterone producing adenomas

Argentesi Giulia , Wu Xilin , Goodchild Emily , Laycock Kate , Ney Alexander , Senanayake Russell , MacFarlane James , Goodchild George , Wilson Patrick , Godfrey Ed , Gurnell Mark , Cheow Heok , P Pereira Stephen , M Drake William , J Brown Morris

Primary aldosteronism (PA) is the potentially curable cause of high-risk hypertension in 5-10% of unselected patients. Diagnosis and lateralisation of PA is challenging and complex. Outcomes post total adrenalectomy, the standard treatment for unilateral aldosterone producing adenomas (APAs), are variable. Between 30-60% are cured (1), but prediction of outcome is unreliable, and some patients are reluctant to have abdominal surgery to remove a whole adrenal gland. Endoscopic ...

ea0094p233 | Neuroendocrinology and Pituitary | SFEBES2023

Characterisation of the Impact of Joint Pain on Patients with Acromegaly

Hebden Sophie , Safdar Nawaz , Heague Megan , Lynch Julie , Mclaren David , Tresoldi Alberto , Lithgow Kirstie , Urwyler Sandrine , Akbar Shahzad , McLoughlin Katie , Kearney Tara , M Drake William , Sathyapalan Thozhukat , Orme Steve , E Higham Claire , Karavitaki Niki , Kyriakakis Nikolaos , Murray Robert

Acromegaly is caused by excessive growth hormone (GH) and insulin-like growth factor (IGF-1) secretion. Arthropathy is a leading cause of morbidity and impaired quality of life in acromegalic patients, often persisting despite therapeutic interventions and biochemical control. This cross-sectional study aimed to characterise the extent and impact of arthropathy in terms of pain and functional impairment. Validated questionnaires, including DASH (Disabilities of the Arm, Should...